Literature DB >> 17659549

Magnetic resonance imaging for ischemic heart disease.

Hajime Sakuma1.   

Abstract

Cardiac MRI has long been recognized as an accurate and reliable means of evaluating cardiac anatomy and ventricular function. Considerable progress has been made in the field of cardiac MRI, and cardiac MRI can provide accurate evaluation of myocardial ischemia and infarction (MI). Late gadolinium (Gd)-enhanced MRI can clearly delineate subendocardial infarction, and the assessment of transmural extent of infarction on late enhanced MRI has been shown to be useful in predicting functional recovery of dysfunctional myocardium in patients after MI. Stress first-pass contrast-enhanced (CE) myocardial perfusion MRI can be used to detect subendocardial ischemia, and recent studies have demonstrated the high diagnostic accuracy of stress myocardial perfusion MRI for detecting significant coronary artery disease (CAD). Free-breathing, whole-heart coronary MR angiography (MRA) was recently introduced as a method that can provide visualization of all three major coronary arteries within a single three-dimensional (3D) acquisition. With further improvements in MRI techniques and the establishment of a standardized study protocol, cardiac MRI will play a pivotal role in managing patients with ischemic heart disease. Copyright 2007 Wiley-Liss, Inc.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17659549     DOI: 10.1002/jmri.20976

Source DB:  PubMed          Journal:  J Magn Reson Imaging        ISSN: 1053-1807            Impact factor:   4.813


  8 in total

1.  MDCT evaluation of cardiac involvement in hypereosinophilic syndrome: differentiating mural thrombus, infarcted, and noninfarcted myocardium by delayed-phase scanning.

Authors:  Chuan-Han Chen; I-Chen Tsai; Sheng-Ling Jan; Wei-Lin Tsai; Clayton Chi-Chang Chen
Journal:  Tex Heart Inst J       Date:  2011

2.  Duchenne muscular dystrophy; a cardiomyopathy that can be prevented?

Authors:  Barbara J M Mulder; Ernst E van der Wall
Journal:  Int J Cardiovasc Imaging       Date:  2008-10-01       Impact factor: 2.357

3.  Referenceless acquisition of phase-sensitive inversion-recovery with decisive reconstruction (RAPID) imaging.

Authors:  Jinnan Wang; Huijun Chen; Jeffrey H Maki; Xihai Zhao; Gregory J Wilson; Chun Yuan; Peter Börnert
Journal:  Magn Reson Med       Date:  2013-11-11       Impact factor: 4.668

4.  Hexylether derivative of pyropheophorbide-a (HPPH) on conjugating with 3gadolinium(III) aminobenzyldiethylenetriaminepentaacetic acid shows potential for in vivo tumor imaging (MR, Fluorescence) and photodynamic therapy.

Authors:  Joseph A Spernyak; William H White; Manivannan Ethirajan; Nayan J Patel; Lalit Goswami; Yihui Chen; Steven Turowski; Joseph R Missert; Carrie Batt; Richard Mazurchuk; Ravindra K Pandey
Journal:  Bioconjug Chem       Date:  2010-05-19       Impact factor: 4.774

5.  Guideline for Cardiovascular Magnetic Resonance Imaging from the Korean Society of Cardiovascular Imaging-Part 1: Standardized Protocol.

Authors:  Yeseul Jo; JeongJae Kim; Chul Hwan Park; Jae Wook Lee; Jee Hye Hur; Dong Hyun Yang; Bae Young Lee; Dong Jin Im; Su Jin Hong; Eun Young Kim; Eun Ah Park; Pan Ki Kim; Hwan Seok Yong
Journal:  Korean J Radiol       Date:  2019-09       Impact factor: 3.500

Review 6.  Assessment and Treatment of Patients With Type 2 Myocardial Infarction and Acute Nonischemic Myocardial Injury.

Authors:  Andrew P DeFilippis; Andrew R Chapman; Nicholas L Mills; James A de Lemos; Armin Arbab-Zadeh; L Kristin Newby; David A Morrow
Journal:  Circulation       Date:  2019-08-16       Impact factor: 29.690

7.  Feasibility of perfusion cardiovascular magnetic resonance in paediatric patients.

Authors:  Emanuela R Valsangiacomo Buechel; Christian Balmer; Urs Bauersfeld; Christian J Kellenberger; Juerg Schwitter
Journal:  J Cardiovasc Magn Reson       Date:  2009-11-30       Impact factor: 5.364

8.  Late contrast enhancement by CMR: more than scar?

Authors:  Ernst E van der Wall; Jeroen J Bax
Journal:  Int J Cardiovasc Imaging       Date:  2008-04-23       Impact factor: 2.357

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.